Curis, Inc., a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced that it has formed a wholly foreign-owned enterprise form of subsidiary in Shanghai, China. Earlier in 2006, Curis had initiated development work on several proprietary cancer programs through its relationship with Shanghai ChemPartner, a leading Chinese medicinal chemistry contract researcher. With the establishment of Curis Pharmaceuticals (Shanghai) Co., Ltd. ("Curis Shanghai"), Curis will seek to leverage China's mature, cost-efficient medicinal chemistry industry as a means of broadening Curis' pipeline of drug programs.

Curis joins a growing number of U.S. pharmaceutical and biotechnology companies that have established collaborative relationships in China. Many of the largest companies in the pharmaceutical industry have established a presence in China, either through subsidiaries or through service contracts with Chinese medicinal chemistry providers, tapping into the country's extensive intellectual capital and advantageous economic environment. Curis will combine a subsidiary presence with expansion of its current contractual agreement with Shanghai ChemPartner.

Daniel R. Passeri, President and CEO of Curis, Inc., stated, "Our increased development efforts in China, as typified by the formation of Curis Shanghai, should prove to be an important asset for Curis."

Source:佚名